Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 31 for “"endocrine therapy"”.
-
Targeting mdr1 and endocrine therapy-resistant cancers through estrogen receptor
… BHPI blocked growth and often killed diverse therapy-resistant and ER-positive breast, ovarian, and endometrial cancer cells. Moreover, in a mouse xenograft, BHPI treatment resulted in rapid and substantial regression of pre-existing tumors. Extending the novel action of BHPI by …
-
Endocrine therapy mediated hot flushes in breast cancer: can exercise help?
… sweating. Hot flushes are a side effect of endocrine therapy for breast cancer treatment; and are possibly more frequent and severe than post-menopausal hot flushes. Many breast cancer patients do not adhere to the endocrine therapy guidelines due to the frequency and severity of hot …
-
Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting
… rates for ER positive cancers on neoadjuvant endocrine therapy (NET), with lower toxicity compared to neoadjuvant chemotherapy (NCT). During the first wave of the COVID pandemic, clinician preference for NET increased significantly, buying time for hospital recovery before proceeding to …
-
Treatment Side Effects & Nonadherence among Women Taking Adjuvant Endocrine Therapy for Breast Cancer: The Role of Psychological Factors
Nonadherence to adjuvant endocrine therapy with either tamoxifen or aromatase inhibitors significantly increases the risk of breast cancer recurrence. Side effects are a key driver of nonadherence to these treatments. As part of this doctoral research, two studies were conducted to explore the …
-
Racial Differences in Distress Symptoms Among Black and White Women with Hormone Receptor-Positive Breast Cancer on Adjuvant Endocrine Therapy
… to their lower adherence rates to adjuvant endocrine therapy (AET) compared to their White counterparts. Understanding the trajectories of distress and depression among breast cancer survivors, particularly through the lens of racial differences, is crucial for developing effective …
-
The decision making process in women diagnosed with estrogen receptor-positive breast cancer experiencing side effects related to oral endocrine therapy
Oral endocrine therapy (OET) is standard therapy for millions of estrogen receptor-positive breast cancer survivors (ER+BCS). OET reduces recurrence, mortality, and metastasis. ER+BCS often do not take their OET as recommended due to adverse side effects. The purpose of this dissertation was to …
-
The RESILIENT Study: A Retrospective, Descriptive, Correlational Investigation of Rate and Correlates of Oral Endocrine Therapy Adherence in Older Women with Breast Cancer
… About 80% of breast cancer patients take oral endocrine therapy (OET), such as anastrozole, letrozole, tamoxifen, and exmestane. These medications increase survival, improve quality-of-life and decrease healthcare costs, yet many patients do not take it properly. The purpose of this study is to …
-
Proteomic Investigation of Endocrine Therapy Resistance in Breast Cancer Investigating the Molecular Mechanisms for SERM Resistant Cell Lines Using SILAC-Based Proteomic Approach
… of cancer mortality in women worldwide. Hormonal therapy is considered one of the most effective therapies and is used against luminal-type malignancies. However, 40-50% of tumour cells can develop resistance, thereby limiting the success in breast cancer treatment. In this study, mechanisms of …
-
Comprehensive gene assessment of estrogen receptor positive breast cancers reveals that HER2 positive status plays an important role in resistance to neoadjuvant letrozole
… HER2+ positive cancers exhibit resistance to endocrine therapy, yet it is unclear what is driving this resistance to therapy. The challenge is in identifying, early in the process of treatment decision making, who will respond to neoadjuvant letrozole therapy and who might benefit from the …
-
The role of metabolic rewiring in endocrine resistance
… occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to prevent or delay recurrence of ERα (+) tumors. The overall objective of this dissertation project is to define the interaction among endocrine resistance, nuclear export …
-
Ανοσοϊστοχημική μελέτη της έκφρασης των οιστρογονικών υποδοχέων στους όγκους των ωοθηκών με μονοκλωνικά αντισώματα (με την μέθοδο αβιντίνης-βιοτίνης)
… carcinomas, are candidates for antiestrogen endocrine therapy, adjuvant to surgery and chemotherapy. Our method can detect ER in paraffin sections of ovarian tumors with precision, thus making possible both their retrospective examination and the simultaneous comparison of their …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… of the patients and their response to first-line therapy were investigated. The data analysis was retrospective. All patients provided histological samples for examination after signing informed consent. Some of the patients were diagnosed at the metastatic stage, while others were diagnosed at an …
-
Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells
… the continuous application of any targeted therapy often results in resistance to the therapy. Our ultimate goal is to use mathematical modelling to optimize alternating therapies that not only decrease proliferation but also stave off resistance. Toward this end, we measured levels of key …
-
Symptoms Experienced By Post-Menopausal Breast Cancer Survivors On Aromatase Inhibitors: A Secondary Analysis Of Baseline Data
<p>Background: Endocrine therapy for breast cancer with Aromatase Inhibitors (AI) is designed to reduce risk of recurrence and improve survival. AI therapy is associated with a variety of symptoms including musculoskeletal complaints, which have contributed to discontinuation of treatment. It is …
-
Identifying new actions of estrogen receptor targetable with small molecules
… some ovarian, endometrial, and cervical cancers. Endocrine therapy targeting these cancers often leads to development of resistance. Ovarian cancers do not respond to endocrine therapy. The presence of ERα in many resistant tumors suggested the existence of additional modes of ERα action that …
-
Necrotic cell death: A novel outcome of BHPI-hyperactivation of the anticipatory unfolded protein response
… The standard of care for these cancers is endocrine therapy, including aromatase inhibitors and selective estrogen receptor modulators and degraders (SERMs and SERDs), that either block the production of estrogen or competitively inhibit the binding of estrogen to ERa. These small molecule …
-
The anticipatory unfolded protein response and estrogen receptor mutations in breast cancer
… cancer cell proliferation and metastasis. Endocrine therapy targeting E2:ERα activity often leads to development of antiestrogen resistance. Approximately 30% of patients who have metastatic endocrine therapy resistant breast cancer express ERα mutations. Two of the most common and …
-
Decision-making in older women with breast cancer: a mixed methods study
… and faced with a choice of surgery or primary endocrine therapy (PET). Research design and methods This exploratory, sequential mixed methods study comprised a critical review of the literature, qualitative interviews and a quantitative questionnaire. The findings were interpreted and …
-
The impact of ARID1A loss on ER+ breast cancer: mechanistic insights and therapeutic opportunities
… ARID1A mutations contribute to resistance to endocrine therapy in breast tumours while simultaneously increasing their sensitivity to epigenetic BET inhibitors. This project aims to explore the role of ARID1A loss in driving metastatic ER+ breast cancer, using the most clinically relevant …
-
The role of human DEAD-box protein DDX3X in the activation and function of Estrogen Receptor-alpha
… of DDX3 in breast cancer and linking it to endocrine therapy resistance.
Page 1 of 2